Abstract: Disclosed herein are an oil-extracted product of indigo naturalis, and the preparation process thereof. Also disclosed are a pharmaceutical composition containing the oil-extracted product of indigo naturalis and a method for treating a human subject having or suspected to have a psoriatic disease such as skin psoriasis and nail psoriasis.

Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said dermatological/cosmetic composition having physical stability without loss of viscosity over time at a temperature ranging from 4° C. to 40° C., said dermatological/cosmetic composition having a stable flow threshold over time as measured by viscosity measurements for rheograms which measure a shear stress ? for a given rate gradient ? and which measure a rate gradient ? for a given shear stress ?, the yield value (?0) being extrapolated visually or by calculation.

Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Abstract: The invention relates to a pharmaceutical or cosmetic composition comprising, in a physiologically acceptable medium, mequinol and at least one depigmenting agent, and to the use thereof.

Abstract: Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.

Abstract: The invention relates to the use of a modulator of at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor for the preparation of a pharmaceutical composition for treating rosacea.

Abstract: The invention relates to use of metronidazole for the preparation of a pharmaceutical composition for treating cutaneous inflammation, and preferentially the inflammatory component of rosacea.

Abstract: The invention relates to the use of an antagonist of at least one receptor chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor, for the preparation of a pharmaceutical composition for treating rosacea.

Abstract: The invention relates to the use of idrocilamide for the preparation of novel pharmaceutical compositions, more particularly dermatological compositions, which can be used to treat rosacea.

Abstract: The invention relates more particularly to the use of metronidazole for the preparation of a pharmaceutical composition for treating a cutaneous vascularization disorder.

Abstract: The invention relates to the use of a compound which modifies, and advantageously inhibits, the secretion of at least one interleukin chosen from the group comprising IL-5, IL-6 and IL-10, for the preparation of a pharmaceutical composition for treating rosacea.

Abstract: The invention relates to the use of fepradinol for the production of novel pharmaceutical compositions, in particular, dermatological compositions, of use for the treatment of rosacea.

Abstract: The invention relates to novel stilbene compounds having the general formula (I): as well as to pharmaceutical compositions for use in human or veterinary medicine, including dermatological, rheumatic, respiratory, cardiovascular and ophthalmic conditions and cosmetic compositions and methods of use thereof.

Abstract: The invention concerns novel diarylselenide compounds corresponding to the general formula (I) and the use thereof in pharmaceutical compositions in human or veterinary medicine (in the treatment of dermatological, rheumatic, cardiovascular and ophthalmologic pathologies in particular), or in cosmetic compositions.

Abstract: The invention relates to novel biaromatic compounds which correspond to the general formula (I) below: and also to the method for preparing them and their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or alternatively in cosmetic compositions.

Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds having the structural formula (I): in which Ar1 is a radical having one of the structural formulae (a)-(c): and Ar2, X1, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined in the specification.

Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

Abstract: Novel pharmaceutical/cosmetic compositions contain at least one biaromatic ligand activator of a PPAR? receptor, such biaromatic ligand having the structural formula (I): and are well suited, inter alia, for regulating and/or restoring skin lipid metabolism, for treating a wide variety of dermatological afflictions, and for preventing and/or treating the signs of aging and/or dry skin.

Abstract: The invention relates to a novel process for synthesizing organic compounds of general formula (I): said process may be carried out on an industrial scale and makes it possible to obtain from a mixture of racemic alcohols of formula (II), the corresponding chiral alcohols of R configuration, in a high chemical yield.

Abstract: A variety of retinoid compounds well suited for preventively or curatively treating a bacterial colonization infesting/infecting an individual subject exhibit pronounced antibacterial activity, notably pronounced antibacterial activity in respect of the bacterium Staphylococcus aureus, and are also well suited for the cleansing/deodorizing of human skin.